AstraZeneca To Cut 2,300 Sales Jobs As Research to Narrow

Bloomberg reports that AstraZeneca will concentrate on respiratory, inflammation and autoimmune diseases, cardiovascular and metabolic illnesses, and cancer, the London-based drugmaker said in a statement today before a briefing for investors on new Chief Executive Officer Pascal Soriot’s strategy for the company. It also plans to double the number of drugs in late-stage development by 2016.

The job cuts are in addition to 1,600 research positions that the company, the U.K.’s second-biggest drugmaker, said on March 18 it would eliminate. Including a February 2012 plan to cut 1,150 posts, AstraZeneca has announced the elimination of 5,050 jobs in 13 months.

Hit the link below to access the complete Bloomberg article:

AstraZeneca to Cut 2,300 Sales Jobs as Research to Narrow

Oracle Sales and Profit Miss Amid Cloud Competition

Vivendi Back to Square One Weighing French Mobile Spinoff

image: © Torpe